You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
30 April 2024
Spexis receives approval of an extension of the deadline for the publication of its 2023 annual report and audited financials until latest May 31, 2024.
17 April 2024
Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera
8 February 2024
Spexis announces closing of sale of preclinical antibiotics program to Basilea
15 January 2024
Spexis announces sale of preclinical antibiotics program to Basilea
5 December 2023
Spexis is Granted Debt-Restructuring Moratorium
29 November 2023
Spexis Provides Update Regarding Debt-Restructuring Moratorium
18 July 2023
Original-Research: Spexis AG (von First Berlin Equity Research GmbH): Buy
25 January 2023
